Abstract: Objective To evaluate the safety and efficacy of Endostar combined with chemotherapy in the treatment of end-stage
colorectal cancer. Methods The relevant randomized controlled trials were retrieved from the electronic databases of Cochrane
library, PubMed, EMbase, CNKI, CBM, VIP and Chinese Medical Association. The retrieval time limit was from the database
construction to January 2013. The data were extracted from eligible studies assessed for methodological quality according to
Cochrane handbook for systematic reviews and analyzed using RevMan 5.2 software. Results Five randomized controlled
trials involving 220 cases were included for meta-analysis. The results showed that Endostar combined with chemotherapy
had an overall advantage over chemotherapy alone in terms of complete response rate (RR=4.08, 95% CI: 1.19-13.95, P=0.02),
partial response rate (RR=2.18, 95% CI: 1.23-3.87, P=0.007), no response rate (RR=0.25, 95% CI: 0.13-0.47, P<0.0001), and the
overall response rate (RR=3.23, 95% CI: 1.79-5.81, P<0.0001). The main adverse reactions included nausea, vomiting,
constipation, palpitation, and electrocardiogram changes. Conclusion Endostar combined with chemotherapy is effective for
advanced colorectal cancer and can be used as a routine treatment.